| Dr Paul Koutras, MD | |
|
580 Court St, Keene, NH 03431-1715 | |
| (603) 354-6580 | |
| (603) 357-0059 |
| Full Name | Dr Paul Koutras |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 34 Years |
| Location | 580 Court St, Keene, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952367278 | NPI | - | NPPES |
| 30010687 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 10089 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cheshire Medical Center | Keene, NH | Hospital |
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Valley Regional Hospital | Claremont, NH | Hospital |
| Monadnock Community Hospital | Peterborough, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology Associates Of Keene Pc | 5698871960 | 4 |
News Archive
LHC Group, Inc., a national provider of home health and hospice, announced today that it has signed a definitive agreement with Idaho Home Health and Hospice. Founded in 1977, Idaho Home Health and Hospice is a Joint Commission Accredited home health and hospice provider which currently serves 28 counties through 9 locations in the state of Idaho.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The Wall Street Journal on Saturday examined how forms that outline the medical privacy rule under the Health Insurance Portability and Accountability Act "essentially detai[l] the many ways a doctor can use and disclose medical information - often without a patient's consent or knowledge" - and how patients who visit physician offices, hospitals and pharmacies mistakenly "assume signing somehow protects their privacy".
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration for use of the company's next generation mammography computer-aided detection platform, PowerLook Advanced Mammography Platform, with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.
Results of a Dutch study show that the majority of fetuses with fetal echogenic bowel carry a good prognosis.
› Verified 7 days ago
| Entity Name | Radiology Associates Of Keene Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023074390 PECOS PAC ID: 5698871960 Enrollment ID: O20070502000500 |
News Archive
LHC Group, Inc., a national provider of home health and hospice, announced today that it has signed a definitive agreement with Idaho Home Health and Hospice. Founded in 1977, Idaho Home Health and Hospice is a Joint Commission Accredited home health and hospice provider which currently serves 28 counties through 9 locations in the state of Idaho.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The Wall Street Journal on Saturday examined how forms that outline the medical privacy rule under the Health Insurance Portability and Accountability Act "essentially detai[l] the many ways a doctor can use and disclose medical information - often without a patient's consent or knowledge" - and how patients who visit physician offices, hospitals and pharmacies mistakenly "assume signing somehow protects their privacy".
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration for use of the company's next generation mammography computer-aided detection platform, PowerLook Advanced Mammography Platform, with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.
Results of a Dutch study show that the majority of fetuses with fetal echogenic bowel carry a good prognosis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Koutras, MD 217 Old Homestead Hwy, Swanzey, NH 03446-2140 Ph: (603) 352-5881 | Dr Paul Koutras, MD 580 Court St, Keene, NH 03431-1715 Ph: (603) 354-6580 |
News Archive
LHC Group, Inc., a national provider of home health and hospice, announced today that it has signed a definitive agreement with Idaho Home Health and Hospice. Founded in 1977, Idaho Home Health and Hospice is a Joint Commission Accredited home health and hospice provider which currently serves 28 counties through 9 locations in the state of Idaho.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The Wall Street Journal on Saturday examined how forms that outline the medical privacy rule under the Health Insurance Portability and Accountability Act "essentially detai[l] the many ways a doctor can use and disclose medical information - often without a patient's consent or knowledge" - and how patients who visit physician offices, hospitals and pharmacies mistakenly "assume signing somehow protects their privacy".
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration for use of the company's next generation mammography computer-aided detection platform, PowerLook Advanced Mammography Platform, with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.
Results of a Dutch study show that the majority of fetuses with fetal echogenic bowel carry a good prognosis.
› Verified 7 days ago
Dr. Janelle Lira Park, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-5400 | |
Dr. Steven Levene, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-6500 Fax: 603-357-5768 | |
Dr. Jacqueline Marie Lyon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-5400 | |
Dr. Michael Sarson, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-6580 Fax: 603-357-0059 |